<div id="readability-page-1"><p>Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totaling 15,949,282 shares,  an increase of 24.4% from the December 15th total of 12,819,308 shares. Based on an average daily volume of 5,642,145 shares, the short-interest ratio is presently 2.8 days. Currently, 10.7% of the shares of the company are sold short. Currently, 10.7% of the shares of the company are sold short. Based on an average daily volume of 5,642,145 shares, the short-interest ratio is presently 2.8 days.</p><h2>Wall Street Analyst Weigh In</h2><p>PALI has been the topic of several research analyst reports. Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of Palisade Bio in a research note on Wednesday, October 8th. Piper Sandler initiated coverage on shares of Palisade Bio in a research note on Monday, December 29th. They issued an &#34;overweight&#34; rating and a $25.00 price objective for the company. Clear Str upgraded Palisade Bio to a &#34;strong-buy&#34; rating in a research report on Monday, December 29th. B. Riley assumed coverage on Palisade Bio in a research report on Friday, January 9th. They issued a &#34;buy&#34; rating and a $7.00 price target for the company. Finally, Citigroup  reiterated a &#34;buy&#34; rating on shares of Palisade Bio in a research note on Tuesday, November 11th. One equities research analyst  has rated the stock with a Strong Buy rating, four have assigned  a Buy rating and one  has assigned  a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $16.00.</p><p><b>Check Out Our Latest Report on PALI</b></p><h2>Palisade Bio Stock Performance</h2><p>Shares of PALI stock traded down $0.09 on Monday, hitting $1.66. 9,796,958 shares of the company's stock traded hands, compared to its average volume of 5,545,150. The stock has a market capitalization of $247.34 million, a price-to-earnings ratio of -0.78 and a beta of 1.43. The company's fifty day simple moving average is $2.02 and its 200 day simple moving average is $1.42. Palisade Bio has a one year low of $0.53 and a one year high of $2.64. </p><p>Palisade Bio (NASDAQ:PALI - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.06).  As a group, sell-side analysts anticipate that  Palisade Bio will post -12.43 earnings per share for the current fiscal year. </p><h2>Palisade Bio Company Profile</h2> (Get Free Report)<p>Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity. </p><p>The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Palisade Bio</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>Do not delete, read immediately</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>Executive Order 14330: Trump’s Biggest Yet</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Palisade Bio Right Now?</h2><p>Before you consider Palisade Bio, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palisade Bio wasn't on the list.</p><p>While Palisade Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Palisade Bio, Inc. (NASDAQ:PALI) experienced a significant increase in short interest of 24.4% in December, totaling 15,949,282 shares by December 31. This represents 10.7% of the company's stock sold short, with a short-interest ratio of 2.8 days based on an average daily volume of 5,642,145 shares. Analysts have mixed ratings on the stock, with one strong buy, four buys, and one sell, and a consensus target price of $16.00. The stock traded at $1.66, with a market cap of $247.34 million and a P/E ratio of -0.78.</p>

Market Beat

iShares US Pharma

Palisade Bio

VanEck Biotech ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bear 3X

Health Care Select Sector SPDR

SPDR S&P Biotech

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

VG Health

First Trust NYSE Arca Biotech Index Fd

Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Up 24.4% in December